ArticleNature medicine2016
Protection against malaria at 1 year and immune correlates following PfSPZ vaccination.
Erratum issued 3 registry-linked trialsOpen access · greenAbstract readClinical Trial, Phase I
In one paragraph
Article in Nature medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 3 registered trials, which are not on this map. Cited by 237 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
237citing papers in PubMed, 1 pooled it
45.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Trial of PfSPZ Vaccine Administered by Direct Venous Inoculation: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults
A Phase 1, Dose Escalation, Open-Label Clinical Trial With Experimental Controlled Human Malaria Infections (CHMI) to Evaluate Safety and Protective Efficacy of an Anti-Malaria Human Monoclonal Antibody, VRC-MALMAB0100-00-AB (CIS43LS), in Healthy, Malaria-Naive Adults
VRC 614: A Phase 1, Dose Escalation, Open-Label Clinical Trial With Experimental Controlled Human Malaria Infections (CHMI) to Evaluate Safety and Protective Efficacy of an Anti-Malaria Human Monoclonal Antibody, VRC-MALMAB0114-00-AB (L9LS), in Healthy Malaria-Naive Adults
Who cites it
237 citing papers in PubMed, 1 synthesis or guideline pooled it, 374 citations in OpenAlex.
- Pooled it
- Safety, tolerability and immunogenicity of a condensed, multi-dose prime regimen of PfSPZ Vaccine for the prevention of Plasmodium falciparum malaria infection.Malaria journal · 2025Trial
- Single immunization with genetically attenuated Pf∆mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trial.Nature medicine · 2025Trial
- Immune responses associated with protection induced by chemoattenuated PfSPZ vaccine in malaria-naive Europeans.JCI insight · 2024Trial
- Innate immune activation restricts priming and protective efficacy of the radiation-attenuated PfSPZ malaria vaccine.JCI insight · 2024Trial
- Safety and protective efficacy of PfSPZ Vaccine administered to HIV-negative and -positive Tanzanian adults.The Journal of clinical investigation · 2024Trial
- Safety and Immunogenicity of Radiation-Attenuated PfSPZ Vaccine in Equatoguinean Infants, Children, and Adults.The American journal of tropical medicine and hygiene · 2023Trial
- A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria.Science translational medicine · 2022Trial
- Trial
- Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial.The Lancet. Infectious diseases · 2022Trial
- Systems analysis of immune responses to attenuated P. falciparum malaria sporozoite vaccination reveals excessive inflammatory signatures correlating with impaired immunity.PLoS pathogens · 2022Trial
- Repeat controlled human malaria infection of healthy UK adults with blood-stageFrontiers in immunology · 2022Trial
- Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial.Nature medicine · 2021Trial
- Trial
- Trial
- Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humans.Cell reports · 2021Trial
- Trial
- Increase of Dose Associated With Decrease in Protection Against Controlled Human Malaria Infection by PfSPZ Vaccine in Tanzanian Adults.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Trial
- Chemoprophylaxis Vaccination: Phase I Study to Explore Stage-specific Immunity to Plasmodium falciparum in US Adults.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Trial
- Safety, Tolerability, and Immunogenicity of Plasmodium falciparum Sporozoite Vaccine Administered by Direct Venous Inoculation to Infants and Young Children: Findings From an Age De-escalation, Dose-Escalation, Double-blind, Randomized Controlled Study in Western Kenya.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Trial
177 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
56 authors at 8 institutions in 2 countries.
Andrew S IshizukaVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.ORCID 0000-0002-3024-7536
Kirsten E LykeInstitute for Global Health, Center for Vaccine Development and Division of Malaria Research, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Adam DeZureVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
Andrea A BerryInstitute for Global Health, Center for Vaccine Development and Division of Malaria Research, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Thomas L RichieSanaria Inc., Rockville, Maryland, USA.
Floreliz H MendozaVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
Mary E EnamaVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
Ingelise J GordonVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
Lee-Jah ChangVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
Uzma N SarwarVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
Kathryn L ZephirVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
LaSonji A HolmanVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
Eric R JamesSanaria Inc., Rockville, Maryland, USA.
Peter F BillingsleySanaria Inc., Rockville, Maryland, USA.
Anusha GunasekeraSanaria Inc., Rockville, Maryland, USA.
Sumana ChakravartySanaria Inc., Rockville, Maryland, USA.
Anita ManojSanaria Inc., Rockville, Maryland, USA.
MingLin LiSanaria Inc., Rockville, Maryland, USA.
Adam J RubenSanaria Inc., Rockville, Maryland, USA.
Tao LiSanaria Inc., Rockville, Maryland, USA.
Abraham G EappenSanaria Inc., Rockville, Maryland, USA.
Richard E StaffordSanaria Inc., Rockville, Maryland, USA.
Natasha K CSanaria Inc., Rockville, Maryland, USA.
Tooba MurshedkarSanaria Inc., Rockville, Maryland, USA.
Hope DeCederfeltPharmaceutical Development Section, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Sarah H PlummerVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
Cynthia S HendelVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
Laura NovikVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
Pamela J M CostnerVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
Jamie G SaundersVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
Matthew B LaurensInstitute for Global Health, Center for Vaccine Development and Division of Malaria Research, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Christopher V PloweInstitute for Global Health, Center for Vaccine Development and Division of Malaria Research, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Barbara FlynnVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
William R WhalenVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
J P ToddVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
Jay NoorVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
Srinivas RaoVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
Kailan Sierra-DavidsonVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
Geoffrey M LynnVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
Judith E EpsteinNaval Medical Research Center (NMRC), Malaria Department, Silver Spring, Maryland, USA.
Margaret A KempDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Gary A FahleDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Sebastian A MikolajczakCenter for Infectious Disease Research, Seattle, Washington, USA.
Matthew FishbaugherCenter for Infectious Disease Research, Seattle, Washington, USA.
Brandon K SackCenter for Infectious Disease Research, Seattle, Washington, USA.
Stefan H I KappeCenter for Infectious Disease Research, Seattle, Washington, USA.
Silas A DavidsonEntomology Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Lindsey S GarverEntomology Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Niklas K BjörkströmCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Martha C NasonBiostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Barney S GrahamVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
Mario RoedererVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
B Kim Lee SimSanaria Inc., Rockville, Maryland, USA.
Stephen L HoffmanSanaria Inc., Rockville, Maryland, USA.
Julie E LedgerwoodVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
Robert A SederVaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda (NIH), Maryland, USA.
National Institutes of Health · USSanaria · USCenter for Infectious Disease Research · USUniversity of Maryland, Baltimore · USNational Institutes of Health Clinical Center · USWalter Reed Army Institute of Research · USKarolinska University Hospital · SENaval Medical Research Command · US
Funding
Influenza and Emerging and Re-emerging Infectious Diseases Vaccine StudiesZIAAI005047 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DROPULIC, LESIA K · 2009 to 2025
$58.4MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2MFlow Cytometry CoreZICAI005101 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ROEDERER, MARIO · 2009 to 2025
$25.7MNon-Human Primate CoreZICAI005103 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI FOULDS, KATHRYN · 2009 to 2025
$22.7MDevelopment of Pre-Erythrocytic Malaria Vaccines and antibodiesZIAAI005107 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SEDER, ROBERT A · 2010 to 2025
$20.7MFunctional And Phenotypic Characterization Of T Cells In ManZIAAI005021 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ROEDERER, MARIO · 2009 to 2022
$14.4MPlasmodium Falciparum Whole Sporozoite Malaria VaccineR44AI055229 · NIAID · SANARIA, INC. · PI HOFFMAN, STEPHEN LEV · 2005 to 2015
$10.0MUniversal Attenuated Sporozoite Vaccine and Challenge SystemR44AI058375 · NIAID · SANARIA, INC. · PI HOFFMAN, STEPHEN LEV · 2006 to 2018
$9.9MMedical Scientist Training Program Training GrantT32GM145449 · NIGMS · DUKE UNIVERSITY · PI Christopher D Kontos · 2022 to 2026
$6.6MIMPROVING MANUFACTURING AND POTENCY OF CRYOPRESERVED MALARIA SPOROZOITE VACCINER44AI058499 · NIAID · SANARIA, INC. · PI HOFFMAN, STEPHEN LEV · 2008 to 2014
$6.0MMechanisms of antibody protection in pre-erythrocytic and blood stage malariaF32AI114113 · NIAID · SEATTLE BIOMEDICAL RESEARCH INSTITUTE · PI WILDER, BRANDON KEITH · 2014 to 2016
$164kIntramural NIH HHS ZIA AI005107NIAID NIH HHS F32 AI114113NIAID NIH HHS R44 AI055229NIAID NIH HHS R44 AI058375NIAID NIH HHS R44 AI058499NIGMS NIH HHS T32 GM007171NIGMS NIH HHS T32 GM145449
Abstract
An attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown. We assessed how vaccine dosage, regimen, and route of administration affected durable protection in malaria-naive adults. After four intravenous immunizations with 2.7 × 10(5) PfSPZ, 6/11 (55%) vaccinated subjects remained without parasitemia following CHMI 21 weeks after immunization. Five non-parasitemic subjects from this dosage group underwent repeat CHMI at 59 weeks, and none developed parasitemia. Although Pf-specific serum antibody levels correlated with protection up to 21-25 weeks after immunization, antibody levels waned substantially by 59 weeks. Pf-specific T cell responses also declined in blood by 59 weeks. To determine whether T cell responses in blood reflected responses in liver, we vaccinated nonhuman primates with PfSPZ Vaccine. Pf-specific interferon-γ-producing CD8 T cells were present at ∼100-fold higher frequencies in liver than in blood. Our findings suggest that PfSPZ Vaccine conferred durable protection to malaria through long-lived tissue-resident T cells and that administration of higher doses may further enhance protection.
Indexed as
Administration, IntravenousAdolescentAdultAnimalsAntibodies, ProtozoanCD8-Positive T-LymphocytesEnzyme-Linked Immunosorbent AssayFemaleHealthy VolunteersHumansImmunogenicity, VaccineImmunoglobulin GInterferon-gammaLiverMacaca mulattaMalaria, FalciparumAntibodies, ProtozoanImmunoglobulin GInterferon-gammaMalaria Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.